SCHEMBL30051132

SCHEMBL30051132

CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 1/20 0.43
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CTSC P53634 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
PRCP P42785 1/20 0.39
BACE1 P56817 1/20 0.39
MASP2 O00187 1/20 0.38
CALCRL Q16602 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30356632 0.90 DPP7 (0.42) DPP7CTSCCYP3A4CYP2D6CYP1A2
SCHEMBL30051748 0.90 DPP7 (0.44) DPP7ALDH1A1SMN1; SMN2CTSCCYP3A4
SCHEMBL10537153 0.90 DPP7 (0.48) DPP7ALDH1A1SMN1; SMN2CTSCCYP3A4
SCHEMBL6401404 0.90 DPP7 (0.48) DPP7ALDH1A1SMN1; SMN2CTSCCYP3A4
SCHEMBL30729221 0.90 DPP7 (0.48) DPP7ALDH1A1SMN1; SMN2CTSCCYP3A4
SCHEMBL30729269 0.90 DPP7 (0.48) DPP7ALDH1A1SMN1; SMN2CTSCCYP3A4
SCHEMBL31072135 0.88 DPP7 (0.47) DPP7ALDH1A1SMN1; SMN2CTSCCYP3A4
SCHEMBL29608354 0.87 DPP7 (0.46) DPP7CTSCCYP3A4CYP2D6CYP1A2
SCHEMBL29591803 0.87 DPP7 (0.46) DPP7CTSCCYP3A4CYP2D6CYP1A2
SCHEMBL30128707 0.87 DPP7 (0.46) DPP7CTSCCYP3A4CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
US-20230312644-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) 2023-10-05 US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP DPP7 62/4885ALDH1A1 3596/4885SMN1; SMN2 4135/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD DPP7 38/4885ALDH1A1 4110/4885SMN1; SMN2 3023/4885
US-20230312644-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SERPINC1, PLAT, F2 DPP7 2122/4885ALDH1A1 1478/4885SMN1; SMN2 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.